Publications by authors named "A A Slavin"
Spintronic devices offer a promising avenue for the development of nanoscale, energy-efficient artificial neurons for neuromorphic computing. It has previously been shown that with antiferromagnetic (AFM) oscillators, ultra-fast spiking artificial neurons can be made that mimic many unique features of biological neurons. In this work, we train an artificial neural network of AFM neurons to perform pattern recognition.
View Article and Find Full Text PDFArticle Synopsis
- IRAK4 is a key player in IL-1R and TLR signaling, making it a target for treating autoimmune diseases.
- Researchers developed KT-474, a powerful and selective IRAK4 degrader that can be taken orally, marking it as the first of its kind tested outside of cancer treatment.
- KT-474 has completed phase I trials in healthy individuals and patients with skin conditions, and has advanced to phase II trials for further evaluation.
Hidradenitis suppurativa (HS) is a chronic inflammatory disease manifesting as painful dermal nodules, abscesses, and tunnels. Activation of the IL-1R/toll-like receptor pathway is strongly implicated in the pathogenesis of HS; thus, the role of a key signaling node, IRAK4, was investigated in a noninterventional study (NCT04440410) that enrolled 30 patients with HS. IRAK4 expression was evaluated in blood and lesional, perilesional, and nonlesional skin biopsies.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers have developed KT-413, a novel dual-function molecule that effectively degrades IRAK4 and key transcription factors, Ikaros and Aiolos, to combat this subtype of lymphoma.
- * KT-413 has shown promising results in preclinical studies, leading to the initiation of a phase 1 clinical trial targeting B-cell lymphomas, particularly those with MYD88 mutations.
Preclinical human inflammatory bowel disease (IBD) mechanisms is one of 5 focus areas of the Challenges in IBD Research 2024 document, which also includes environmental triggers, novel technologies, precision medicine, and pragmatic clinical research. Herein, we provide a comprehensive overview of current gaps in inflammatory bowel diseases research that relate to preclinical research and deliver actionable approaches to address them with a focus on how these gaps can lead to advancements in IBD interception, remission, and restoration. The document is the result of multidisciplinary input from scientists, clinicians, patients, and funders and represents a valuable resource for patient-centric research prioritization.
View Article and Find Full Text PDF